Endocrine SCIE

國(guó)際簡(jiǎn)稱：ENDOCRINE 參考譯名：內(nèi)分泌

主要研究方向：ENDOCRINOLOGY & METABOLISM 非預(yù)警期刊審稿周期：約1.5月

《內(nèi)分泌》(Endocrine)是一本由Springer US出版的以ENDOCRINOLOGY & METABOLISM為研究特色的國(guó)際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評(píng)論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開(kāi)放期刊，近三年沒(méi)有被列入預(yù)警名單。

3區(qū) 中科院分區(qū)
Q2 JCR分區(qū)
342 年發(fā)文量
3 IF影響因子
未開(kāi)放 是否OA
74 H-index
1995 創(chuàng)刊年份
12 issues per year 出版周期
English 出版語(yǔ)言

Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology.

Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted.

Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.

[ 查看全部 ]

投稿咨詢加急咨詢

Endocrine期刊信息

ISSN：1355-008X
出版語(yǔ)言：English
是否OA：未開(kāi)放
E-ISSN：1559-0100
出版地區(qū)：UNITED STATES
是否預(yù)警：否
出版商：Springer US
出版周期：12 issues per year
創(chuàng)刊時(shí)間：1995
開(kāi)源占比：0.2095
Gold OA文章占比：24.97%
OA被引用占比：0.1500...
出版國(guó)人文章占比：0.17
出版撤稿占比：0.0026...
研究類文章占比：80.70%

Endocrine CiteScore評(píng)價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

6.5

0.844

0.941

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Endocrinology, Diabetes and Metabolism	Q2	79 / 244	67%
大類：Medicine 小類：Endocrinology	Q2	48 / 128	62%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對(duì)2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評(píng)論、會(huì)議論文、書(shū)籍章節(jié)和數(shù)據(jù)論文。

Endocrine中科院評(píng)價(jià)數(shù)據(jù)

中科院 2023年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	3區(qū)

中科院 2022年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	3區(qū)

中科院 2021年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	3區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	3區(qū)

中科院 2021年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	3區(qū)

中科院 2020年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	2區(qū)	ENDOCRINOLOGY & METABOLISM 內(nèi)分泌學(xué)與代謝	3區(qū)

Endocrine JCR評(píng)價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ENDOCRINOLOGY & METABOLISM	SCIE	Q2	88 / 186	53%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ENDOCRINOLOGY & METABOLISM	SCIE	Q2	91 / 186	51.34%

Endocrine歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Endocrine中國(guó)學(xué)者發(fā)文選摘

1、Machine learning-based prediction of diagnostic markers for Graves' orbitopathy
Author: Cai, Yunying; Su, Heng; Si, Yongting; Ni, Ninghua

Journal: ENDOCRINE. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s12020-023-03349-z
2、Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study
Author: Wang, Shiwei; Wang, Yu; Zhu, Li; He, Liang; Lv, Mutian; Zhang, Hao; Wang, Haoyu; Zhang, Fan; Lai, Yaxin; Li, Yushu; Shan, Zhongyan; Teng, Weiping

Journal: ENDOCRINE. 2023; Vol. 79, Issue 1, pp. 113-124. DOI: 10.1007/s12020-022-03186-6
3、Mutation screening of eight genes and comparison of the clinical data in a Chinese cohort with congenital hypothyroidism
Author: Li, Liangshan; Li, Xiaole; Wang, Xiaoyu; Han, Mengmeng; Zhao, Dehua; Wang, Fang; Liu, Shiguo

Journal: ENDOCRINE. 2023; Vol. 79, Issue 1, pp. 125-134. DOI: 10.1007/s12020-022-03188-4
4、2021 Asia-Pacific Graves' Disease Consortium Survey of Clinical Practice Patterns in the Management of Graves' Disease
Author: Parameswaran, Rajeev; de Jong, Mechteld Christine; Kit, James Lee Wai; Sek, Kathleen; Tran Quang Nam; Tran Viet Thang; Nguyen Thy Khue; Than Than Aye; Phone Myint Tun; Cole, Timothy; Miller, Julie A.; Villa, Michael; Khiewvan, Benjapa; Sirinvaravong, Sirinart; Sin, Yong Lit; Muhammad, Rohaizak; Jap, Tjin Shing; Agrawal, Amit; Rajput, Rajesh; Fernando, Ranil; Sumanatilleke, Manilka; Suastika, Ketut; Shong, Young Kee; Lang, Brian; Bartalena, Luigi; Yang, Samantha Peiling

Journal: ENDOCRINE. 2023; Vol. 79, Issue 1, pp. 135-142. DOI: 10.1007/s12020-022-03193-7
5、Global Burden of osteoarthritis associated with high body mass index in 204 countries and territories, 1990-2019: findings from the Global Burden of Disease Study 2019
Author: Zhao, Gaichan; Zhu, Shijie; Zhang, Faxue; Zhang, Xupeng; Zhang, Xiaowei; Li, Tianzhou; Li, Dejia; Zhu, Wei

Journal: ENDOCRINE. 2023; Vol. 79, Issue 1, pp. 60-71. DOI: 10.1007/s12020-022-03201-w
6、Roxadustat improves renal osteodystrophy by dual regulation of bone remodeling
Author: Li, Luyao; Li, Afang; Gan, Liangying; Zuo, Li

Journal: ENDOCRINE. 2023; Vol. 79, Issue 1, pp. 180-189. DOI: 10.1007/s12020-022-03199-1
7、Clinical characteristics and prognostic nomogram for patients with insular thyroid carcinoma: a population-based analysis
Author: Yin, Lei; Hou, Shuang; Hou, Li-Li; Pu, Chen-Chen

Journal: ENDOCRINE. 2023; Vol. 79, Issue 2, pp. 331-341. DOI: 10.1007/s12020-022-03200-x
8、The combination of early identification, chemotherapy, and autologous stem cell transplantation obtained favorable outcomes in unilateral primary adrenal lymphoma: A case report
Author: Huang, Lu; Shuai, Xiao; Zhang, Tingting; Kuang, Pu; Zhang, Dan; Chen, Tao; Tian, Haoming; Xiang, Bing; Ren, Yan

Journal: ENDOCRINE. 2023; Vol. 79, Issue 1, pp. 49-54. DOI: 10.1007/s12020-022-03138-0